To amend title V of the Public Health Service Act to reauthorize the Minority Fellowship Program.
Summary
HR9044 reauthorizes the Minority Fellowship Program under the Public Health Service Act, but it is a procedural authorization without specified funding. The bill is in early legislative stages (referred to committee) and has no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9044 is a procedural reauthorization with no funding specified.
- 2.The Minority Fellowship Program is a small grant program unlikely to affect major healthcare companies.
- 3.The bill is in early stage; no market catalysts from this legislation.
Market Implications
The bill has no direct market implications. Healthcare sector companies such as $UNH, $CNC, and $MOH are not materially affected by a small fellowship program. Investors should focus on broader healthcare policy developments with fiscal impact.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Veterans SPORT Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.